The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP measurement is consistently inferior to that of all other drug classes .
Because outcome data at this dose are lacking , HCTZ is an inappropriate first-line drug for the treatment of hypertension
OBJECTIVES The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide ( HCTZ ) by ambulatory blood pressure ( BP ) monitoring .
BACKGROUND HCTZ is the most commonly prescribed antihypertensive drug worldwide .
More than 97 % of all HCTZ prescriptions are for 12.5 to 25 mg per day .
The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined .
Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension.
1 . Thirty-eight patients with mild to moderate essential hypertension ( seated diastolic 95 - 110 mm Hg ) were r and omized double-blind to treatment with either zofenopril ( n = 19 ) or hydrochlorothiazide ( n = 19 ) over a period of 12 weeks . 2 . Office blood pressure , heart rate , side effects and metabolic changes were assessed at the end of the run-in period on placebo and after 4 , 8 , 12 weeks treatment at the same time , 22 - 24 h after the last dosing . Ambulatory recordings over 14 h ( 8 h to 22 h ) were performed at the end of placebo period and after active treatment for 12 weeks . 3 . The two regimes reduced office blood pressures equally with minimal additional effect seen on increasing the dose . Both zofenopril and hydrochlorothiazide lowered average baseline ambulatory blood pressure , but zofenopril had greater efficacy in reducing BP during some working hours . 4 . Adverse reactions were mild and transient with both drugs . There were no significant changes in laboratory values . 5 . Thus hydrochlorothiazide and zofenopril given once daily at low dosage both reduce office and ambulatory blood pressures and are well tolerated
The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP measurement is consistently inferior to that of all other drug classes .
Because outcome data at this dose are lacking , HCTZ is an inappropriate first-line drug for the treatment of hypertension
OBJECTIVES The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide ( HCTZ ) by ambulatory blood pressure ( BP ) monitoring .
BACKGROUND HCTZ is the most commonly prescribed antihypertensive drug worldwide .
More than 97 % of all HCTZ prescriptions are for 12.5 to 25 mg per day .
The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined .